8th Neuroimmunology Drug Development Summit
Media Partnership
between Immune Discovery and 8th Neuroimmunology Drug Development Summit
The 8th Neuroimmunology Drug Development Summit is the industry’s only meeting fully dedicated to advancing novel neuroinflammatory targets, uniquely bridging cutting-edge academic discovery with the practical lens of drug development. This year’s expanded program goes deeper than ever into emerging glial biology (TREM2 & beyond), peripheral immune pathways, and the technologies redefining how we discover, validate, and measure neuroinflammatory targets.
Across three days, 80+ discovery, preclinical, and translational leaders from Biogen, Sanofi, Merck, Lundbeck, Vigil Neuroscience, Bristol Myers Squibbs and more will unite to share hyper-current insights on merging neuroinflammatory mechanisms, cutting-edge glial models and omics technologies accelerating target discovery, next-generation biomarkers enhancing translation, and early clinical signals from novel neuroimmune-targeting therapies.
Join the global neuroimmunology community this year and help define the future of immune-modulating therapies for the brain.
Find out more in the full Event Guide here: https://ter.li/zoyp2s